UK MHRA · June 04, 2026

Adjuvanted trivalent influenza vaccine authorised for adults aged 50 and over

Original title: Adjuvanted trivalent influenza vaccine authorised for adults aged 50 and over

MHRA grants marketing authorisation for adjuvanted trivalent influenza vaccine for adults aged 50 and over.

Low impact Pharmaceuticals Public Health UK vaccination

The adjuvanted trivalent influenza vaccine works by stimulating the immune system to produce its own protection against flu.

Read the official source ↗

Published by UK MHRA. HealthSignal links to the original document; the summary above is extracted from the source text.